|
Phase
II Prospective Study of CYP2D6 Activity
in Patients With Metastatic or Recurrent
Breast Cancer Treated With Tamoxifen
Citrate (No Drugs Provided)
ECOG E3108
(MBMC Contact: )
Click
For Consent ***
Phase II
Study of Brostallicin and Cisplatin in
Patients With Triple-Negative Metastatic
Breast Cancer (Brostallicin
Provided)
NCCTG N0937 (MBMC Contact: )
Click
For Consent
A Randomized Phase III Trial to Test the Strategy of Changing
Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients
who Have Elevated Circulating Tumor Cell Levels at First Follow-Up
Assessment (No Drugs Provided)
SWOG
S0500
(MBMC Contact:
Chris Sanders 314-996-5802)
Click
For Consent
***
***Available through CTSU
← Previous
|